Aging Research Center, Department of Neurobiology, Care Sciences and Society, Karolinska Institutet and Stockholm University, Gävlegatan 16, 113 30 Stockholm, Sweden.
Osteoporos Int. 2012 Mar;23(3):1061-8. doi: 10.1007/s00198-011-1636-8. Epub 2011 Apr 16.
In this population-based study of more than 2,600 elderly, people with dementia received less preventive treatment for osteoporosis compared to people without dementia, although osteoporotic fractures were more common in patients with dementia. Thus, our results indicate an undertreatment of osteoporosis in dementia.
This study compares the use of osteoporosis drugs in elderly with and without dementia, taking into account osteoporotic fractures and type of housing.
We analyzed data from the baseline examination (2001-2004) of The Swedish National Study on Aging and Care- Kungsholmen (SNAC-K), Stockholm, Sweden. Participants were aged ≥ 66 years (n = 2610). We analysed the use of bisphosphonates, raloxifene, and calcium/vitamin D combinations in relation to clinically based dementia diagnosis. Information about osteoporotic fractures during the previous 4 years was obtained from the Swedish National Patient Register. We used logistic regression to analyze the association between dementia status and use of osteoporosis drugs.
Osteoporosis drugs (mainly calcium/vitamin D combinations) were used by 5% of the persons with dementia and 12% of the persons without dementia. Furthermore, 25% of the persons with dementia and 7% of the persons without dementia had had at least one osteoporotic fracture during the past 4 years. After controlling for age, sex, osteoporotic fractures, and type of housing (own home or institution), persons with dementia were less likely to use osteoporosis drugs than persons without dementia (OR = 0.34; 95% CI, 0.19-0.59).
Our results indicate an undertreatment of osteoporosis in persons with dementia, although osteoporotic fractures are common among these patients.
在这项针对 2600 多名老年人的基于人群的研究中，痴呆症患者接受骨质疏松症预防治疗的比例低于没有痴呆症的患者，尽管痴呆症患者的骨质疏松性骨折更为常见。因此，我们的结果表明痴呆症患者的骨质疏松症治疗不足。
本研究比较了患有和不患有痴呆症的老年人使用骨质疏松症药物的情况，同时考虑了骨质疏松性骨折和住房类型。
我们分析了来自瑞典国家老龄化和护理研究- Kungsholmen（SNAC-K）的基线检查（2001-2004 年）的数据，瑞典斯德哥尔摩。参与者年龄≥66 岁（n=2610）。我们分析了双膦酸盐、雷洛昔芬和钙/维生素 D 联合用药与基于临床的痴呆症诊断的关系。过去 4 年内骨质疏松性骨折的信息来自瑞典国家患者登记处。我们使用逻辑回归分析痴呆症状态与骨质疏松症药物使用之间的关联。
骨质疏松症药物（主要是钙/维生素 D 联合用药）在 5%的痴呆症患者和 12%的非痴呆症患者中使用。此外，25%的痴呆症患者和 7%的非痴呆症患者在过去 4 年内至少有一次骨质疏松性骨折。在控制年龄、性别、骨质疏松性骨折和住房类型（自有住房或机构）后，痴呆症患者使用骨质疏松症药物的可能性低于非痴呆症患者（OR=0.34；95%CI，0.19-0.59）。
尽管这些患者骨质疏松性骨折很常见，但我们的结果表明痴呆症患者的骨质疏松症治疗不足。
